Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4001468 | Urologic Oncology: Seminars and Original Investigations | 2009 | 7 Pages |
Abstract
Livin may serve as a promising marker to identify the relapse risk in bladder cancer, and targeting Livin could offer a therapeutic benefit in apoptosis-inducing treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hai-Bo M.D., Chui-Ze M.D., Yu M.D., Xian-Kui M.D., Jian-Bin M.D., Yuan-Jun M.D., Sheng M.D.,